Autopsy report · NCT05703555

INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

“Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Erasmus Medical Center

Sponsor type

University, hospital or other

Conditions

Metastatic Lung Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer

Interventions

Tusamitamab ravtansine

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
  “Although no safety signal has been observed, given that the industrial development of tuvusertib has been halted regardless of the results, we see no scientific and ethical justification for continuing the study” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.